Attachment 1 Statement of Work (SOW).docx

Department of Defense Defense Health Agency

Statement of Work (SOW)

Contract Title: Comprehensive Clinical and Dental Drug and Pharmacology Reference

Requiring Activity Name: DHA Medical Libraries Organizational Management Office (DML OMO)/Executive Skills, Continuing Education, and Libraries (EXCEL), J-7, Falls Church, VA

Solicitation Number: HT0011-25-R-0053 Version: 1 Date: 05 May 2025

1. Scope and Background

1.1. Scope

This is a statement of work (SOW) for a commercial off-the-shelf (COTS) clinical and dental drug reference. This resource is required as a first-line, comprehensive and primary source of clinical and dental drug information and guidance for Department of Defense (DoD) Medicine and the Military Health System (MHS), which include and consist of medical and clinical support functions, all medical-related personnel regardless of location (CONUS, OCONUS, Military Treatment Facilities (MTFs), shipboard, submarine, forward deployed, or other operational settings), and components located within and belonging to the organizations specified below (here-in known as supported organizations):

· MHS

· Defense Health Agency (DHA)

· DoD Medical Laboratories

· DoD Medical Research Organizations

· Air Force Medicine

· Army Medicine

· Navy Medicine

· Coast Guard Medicine

· United States Air Force

· United States Army

· United States Navy Although part of the MHS, Uniformed Services University of the Health Sciences is excluded from the scope of this SOW.

The contract period of performance will be base year plus 4 option years with a six-month extension period.

1.2. Background

The DoD Medicine and MHS health care professionals require access to a comprehensive drug and pharmacology resource providing drug reference information, guidance, usage, and considerations to providers and clinicians who prescribe, order, dispense, or administer medications. The resource must also provide comprehensive, directed drug information for use in the dental setting.

1.3. Place of Performance: The work to be performed under this contract will be performed at the vendor’s facilities.

1.4. Period of Performance

1.5. The vendor shall provide all personnel, equipment, supplies, facilities, transportation, tools, materials, technical support, supervision, and other items and non-personal services necessary to provide and maintain access to a comprehensive clinical and dental drug and pharmacology reference for supported organizations as defined in this SOW.

1.6. Contracting Officer Representative (COR): The COR will be identified by separate letter. The COR monitors all technical aspects of the contract and assists in contract administration The COR is authorized to perform the following functions: assure that the vendor performs the technical requirements of the contract; perform inspections necessary in connection with contract performance; maintain written and oral communications with the vendor’s concerning technical aspects of the contract; and monitor vendor’s performance and notifies both the Contracting Office and vendor of any deficiencies. A letter of designation issued to the COR, a copy of which is sent to the vender, states the responsibilities and limitations of the COR, especially with regard to changes in cost or price, estimates or changes in delivery dates. The COR is not authorized to change any of the terms and conditions of the resulting contract.

2. Requirements

2.1. Content

2.1.1. The product shall provide drug reference information, guidance, usage, and considerations to providers and clinicians who prescribe, order, dispense, or administer medications. Information shall be available for drugs and related substances used within the United States as well as outside the United States supporting adult, geriatric, pediatric, and neonatal patients.

2.1.2. The product shall address pharmacotherapeutic considerations related to specific patient populations (e.g. adult, geriatric, pediatric, disease state).

2.1.3. References in the product shall hyperlink to their records in PubMed.

2.1.4. Recommendations shall be based on the latest evidence.

2.1.5. Date of last update or review must be clearly indicated on all drug information pages, patient education handouts, and disease, condition, and topic reviews to determine currency of information.

2.1.6. The product shall provide infectious disease reference information.

2.1.7. The product shall have separate patient medication handouts for the pediatric population.

2.1.8. When available, the latest pediatric-specific evidence (meta-analyses, systematic reviews, randomized controlled trials, medical society guidelines) or pediatric standard references (latest editions of Red Book and Nelson’s Pediatric Antimicrobial Therapy) shall be used for recommending pediatric dosing.

2.1.9. The product shall have a pharmacogenomics section which includes dosing recommendations based on pharmacogenomics information.

2.1.10. The product shall provide instructions for converting medications to liquid preparations for medications where there is a clinical need to do so (e.g. certain pediatric medications).

2.1.11. The product shall provide nuclear, biological, chemical, and radiological agent exposure reference information.

2.1.12. The product shall provide references to assist healthcare providers with evaluating the reproductive risks of drugs, chemicals, and physical/environmental agents on males, females, children, and unborn children.

2.1.13. The product shall provide natural products reference information.

2.1.14. The product shall provide full, current access to AHFS Drug Information.

2.1.15. The product shall include subscription drug costs.

2.1.16. The product shall provide guidance in the identification, management, and treatment of patient poisoning and toxicological exposures.

2.1.17. The product shall provide disease, condition, and topic reviews that include etiology, diagnosis, and treatment at the minimum.

2.1.18. The product shall provide I.V. compatible reference information (e.g., calculators, nomograms).

2.1.19. The product shall have patient education handouts on diseases, conditions, and procedures in multiple languages.

2.1.20. The product shall have patient education handouts on medications.

2.1.21. Dental Content

2.1.21.1. The product shall have drug and pharmacology information, guidance, usage, and considerations specific to dentistry and the dental setting.

2.1.21.2. Dental content shall be contained in one dedicated section, under a clear heading, or in a standalone dental product for easy identification and access to optimize efficiency and productivity.

2.1.21.3. The product shall provide disease, condition, and topic reviews specific to dentistry (e.g., Temporomandibular Joint – TMJ).

2.1.21.4. The product shall have patient education handouts specific to dental diseases, conditions, and procedures in multiple languages.

2.2. Functionality

2.2.1. The product shall be searchable by both generic and brand drug names.

2.2.2. The product shall the provide the capability for users to check for interacting drug ingredients (e.g., drug-drug, drug-food, drug-ethanol, drug-disease, drug-allergy)

2.2.3. The product shall support users in different environments (e.g., outpatient, pharmacy, inpatient, emergency room, ICU).

2.2.4. The product shall assist users in the identification of unknown products (e.g., capsules and tablets).

2.2.5. The product shall have a search interface that is customer-friendly and effective at retrieving drugs and medical and dental topic reviews quickly and easily. The product shall have a drop-down menu of possible matches after typing the first few characters (auto-suggest).

2.2.6. The product shall provide a stand-alone complete database that does not require a subscription to other products to retrieve a complete medical topic review.

2.2.7. The product shall provide Food & Drug Administration drug alerts.

2.3. Accessibility

2.3.1. The vendor shall provide direct access to the product over the MHS Medical Community of Interest (Med-COI) Network Internet protocol (IP) architecture.

2.3.2. The vendor shall allow access through COTS remote authentication solutions, including but not limited to OpenAthens Single Sign-On and EZproxy and other Government-approved, secure methods that prevent unauthorized access.

2.3.3. The product shall be capable of unlimited, simultaneous access by authorized users.

2.3.4. The vendor shall allow all authorized users access to the product from any computer, tablet, or mobile device with an Internet or Wi-Fi connection regardless of location.

2.3.5. The vendor shall make all online content and features accessible in their entirety on iOS and Android devices through a single mobile app downloadable from the Apple Store and Google Play. All content and features such as calculators, drug interactions, IV compatibility, etc. shall be available in the mobile app, without requiring the user to download multiple mobile apps. All dental content and features as described in 2.1.19 inclusive shall be available in its entirely in a dedicated dental section of the mobile app or in a standalone mobile app specific for dentistry.

2.3.6. The vendor shall make all online content and features downloadable and accessible in their entirety for use offline (i.e., without Internet or WiFi connection) on iOS and Android devices through a single mobile app downloadable from the Apple Store and Google Play. All content and features such as calculators, drug interactions, IV compatibility, etc. shall be available for offline use in the single mobile app, without requiring the user to download multiple mobile apps. All dental content and features as described in 2.1.19 inclusive shall be available for offline use without Internet or Wi-Fi connection in a dedicated section of the mobile app or in a standalone mobile app specific for dentistry. The vendor shall provide updates in alignment with online updates. Wi-Fi or Internet connection will be made available for initial download and full content updates.

2.4. Support

2.4.1. The vendor shall accept and manage up to 2.5 million IP addresses. The vendor shall have the documented ability to support the Military Health System (MHS) operational networking environment and multiple physical sites within this environment who access content electronically.

2.4.2. The vendor shall support access through Commercial off the Shelf (COTS) authentication solutions, including but not limited to OpenAthens Single Sign-On and EZproxy; and other Government-approved, secure methods that prevent unauthorized access.

2.4.3. The vendor shall provide telephone and email technical support 365/24/7.

2.4.4. The vendor shall provide and support integration throughout the network via the current and future DOD Electronic Health Record (EHR) portal, to ensure consistent access at the bedside for all health professionals and staff.

2.4.5. The vendor shall provide a monthly usage report to the COR and/or designated government civilians in the DML OMO displaying the following at a minimum:

2.4.5.1. Total number of medical and dental searches

2.4.5.2. Total number of topic or page views

2.4.5.3. Total number of registered users

2.4.5.4. Number of new registered users per month

2.4.5.5. Total number of mobile app downloads

2.4.6. The vendor shall provide statistics on demand.

2.4.7. The vendor shall provide onsite and virtual live user training sessions and promotional and instructional flyers and brochures at no additional charge to the Government.

3. Deliverables

3.1. (Deliverable #1) The vendor shall provide access to the product over the Med-COI Network via IP addresses provided by the COR and/or designated government civilian(s) in the DML OMO. The vendor shall enable access from new or updated IP ranges within two business days after notification.

3.2. (Deliverable #2) The vendor shall provide a monthly usage report to the COR by the fifteenth (15th) day of the month per section 2.4.5. of the SOW.

3.3. (Deliverable #3) The vendor shall provide ad-hoc reports as requested by the COR and/or designated government civilian(s) in the DML OMO within five (5) business days of request.

3.4. (Deliverable #4) The vendor shall provide telephone and email technical support 24/7/365 for authorized personnel worldwide. All site content and support of the web site is the responsibility of the vendor. Technical issues unresolved within one 24 hours shall be reported via email to both the COR and the DML OMO at dha.ncr.education-trng.mbx.mhs-medical-library@health.mil.

3.5. (Deliverable #5) System downtime resulting from upgrade or other electronic maintenance requirements shall be minimal, and the vendor shall notify the COR and the DML OMO 10-15 calendar days prior to a scheduled maintenance start date. The vendor shall notify the COR and the DML OMO at dha.ncr.education-trng.mbx.mhs-medical-library@health.mil a minimum of 24 hours before an unplanned system downtime occurs or as soon as a system outage occurs or is noticed.

3.6. (Deliverable #6) The vendor shall provide monthly reports of technical service requests from users to the COR and/or designated government civilian(s) in the DML OMO by the fifteenth (15th) day of the month. Each report shall provide at a minimum the following columns in Excel format with:

3.6.1. Ticket number

3.6.2. Date of creation

3.6.3. Assigned representative

3.6.4. Customer name

3.6.5. Customer email address

3.6.6. Issue/request statement

3.6.7. Status

3.6.8. Result

image1.png